On Jul. 29, 2021, SIGA Technologies announced that it had entered into a collaboration with Oxford University in the United Kingdom to provide TPOXX (tecovirimat) under an expanded access protocol to treat individuals affected by mpox in the Central African Republic (CAR).

Under the agreement, Oxford University sponsor the protocol and study in CAR, and SIGA provided up to 500 courses of TPOXX (tecovirimat) at no cost.

Mpox is endemic in the tropical rainforest regions of Central and West African countries, notably Cameroon, Central African Republic, Cote d’Ivoire, Democratic Republic of the Congo (DRC), Gabon, Liberia, Nigeria, Republic of the Congo and Sierra Leone.